Aligos Therapeutics (ALGS) Stock Forecast & Price Target

Aligos Therapeutics is a promising biotechnology company that has a strong focus on developing treatments for liver diseases and viral infections, with a particular emphasis on their drug candidate, pevifoscorvir sodium. This drug has shown promising results in clinical trials and is being studied for various indications, including hepatitis B and MASH. The company also has a strong partnership with Amoytop and a solid cash position, making it well-equipped to continue its research and development efforts. Therefore, it is not surprising that analysts maintain a positive outlook on the company's stock and maintain a Buy rating with a price target of $50.

Aligos Therapeutics is facing challenges in its clinical development of pevifoscorvir sodium, as its efficacy results may be negatively affected by higher patient baseline viral loads compared to previous studies. Additionally, there is a potential for safety concerns and ALT flares with conventional treatment which may limit its potential success. The company's other drug candidate, ALG-055009, has not garnered sufficient investor interest, and the lack of a partnership and funding may impede its further development. Risks to its stock price also include regulatory changes and competition in the HBV market.